CL2012000948A1 - Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. - Google Patents

Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.

Info

Publication number
CL2012000948A1
CL2012000948A1 CL2012000948A CL2012000948A CL2012000948A1 CL 2012000948 A1 CL2012000948 A1 CL 2012000948A1 CL 2012000948 A CL2012000948 A CL 2012000948A CL 2012000948 A CL2012000948 A CL 2012000948A CL 2012000948 A1 CL2012000948 A1 CL 2012000948A1
Authority
CL
Chile
Prior art keywords
idm
atanol
propinate
hfa
fluticasone
Prior art date
Application number
CL2012000948A
Other languages
English (en)
Spanish (es)
Inventor
Walz Rudi Fueg Lise Marie Mueller
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of CL2012000948A1 publication Critical patent/CL2012000948A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2012000948A 2009-10-16 2012-04-13 Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. CL2012000948A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0918150.4A GB0918150D0 (en) 2009-10-16 2009-10-16 Improved formulations

Publications (1)

Publication Number Publication Date
CL2012000948A1 true CL2012000948A1 (es) 2012-12-14

Family

ID=41462451

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000948A CL2012000948A1 (es) 2009-10-16 2012-04-13 Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.

Country Status (25)

Country Link
US (2) US20120263766A1 (https=)
EP (2) EP3811928A1 (https=)
JP (2) JP5818801B2 (https=)
CN (1) CN102573791B (https=)
AU (1) AU2010305695B2 (https=)
BR (1) BR112012008969B1 (https=)
CA (1) CA2776845C (https=)
CL (1) CL2012000948A1 (https=)
CY (1) CY1123918T1 (https=)
DK (1) DK2488157T3 (https=)
ES (1) ES2859629T3 (https=)
GB (1) GB0918150D0 (https=)
HR (1) HRP20210379T1 (https=)
HU (1) HUE054030T2 (https=)
IL (2) IL219162A0 (https=)
LT (1) LT2488157T (https=)
MX (1) MX372991B (https=)
NZ (1) NZ599900A (https=)
PL (1) PL2488157T3 (https=)
PT (1) PT2488157T (https=)
RS (1) RS61430B1 (https=)
SI (1) SI2488157T1 (https=)
SM (1) SMT202100150T1 (https=)
WO (1) WO2011045429A1 (https=)
ZA (1) ZA201202595B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
EP2819669B1 (de) * 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung
IN2014MN02133A (https=) * 2012-04-11 2015-10-09 Cipla Ltd
GB201321712D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
CN105963282B (zh) * 2016-05-04 2019-04-19 四川普锐特医药科技有限责任公司 一种医用定量吸入气雾剂
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
TR199701169T1 (xx) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Salmeterol i�in �l��lm�� doz inhaleri.
HU219900B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Mért dózist adagoló inhalálóberendezés
JPH101442A (ja) * 1996-06-12 1998-01-06 Taisho Pharmaceut Co Ltd 鼻炎用点鼻薬
WO1998041193A1 (en) * 1997-03-20 1998-09-24 Schering Corporation Preparation of powder agglomerates
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
AU2000250701B2 (en) * 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002024552A2 (en) 2000-09-18 2002-03-28 Glaxo Group Limited Coated can for a metered dose inhaler
ES2260299T3 (es) * 2000-10-09 2006-11-01 3M Innovative Properties Company Formulaciones medicinales en aerosol.
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0201400D0 (en) * 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations

Also Published As

Publication number Publication date
SMT202100150T1 (it) 2021-05-07
JP5818801B2 (ja) 2015-11-18
MX372991B (es) 2020-06-18
LT2488157T (lt) 2021-02-10
EP3811928A1 (en) 2021-04-28
AU2010305695A1 (en) 2012-05-03
BR112012008969B1 (pt) 2021-07-06
CN102573791A (zh) 2012-07-11
CA2776845A1 (en) 2011-04-21
HRP20210379T1 (hr) 2021-04-16
RS61430B1 (sr) 2021-03-31
CN102573791B (zh) 2017-09-22
MX2012004338A (es) 2012-08-01
GB0918150D0 (en) 2009-12-02
IL219162A0 (en) 2012-06-28
EP2488157B1 (en) 2020-12-30
NZ599900A (en) 2014-11-28
CA2776845C (en) 2018-04-24
US20180296468A2 (en) 2018-10-18
WO2011045429A1 (en) 2011-04-21
US20170281529A1 (en) 2017-10-05
JP2013507429A (ja) 2013-03-04
JP2016040286A (ja) 2016-03-24
IL269369A (en) 2019-11-28
HUE054030T2 (hu) 2021-08-30
ES2859629T3 (es) 2021-10-04
CY1123918T1 (el) 2022-05-27
AU2010305695B2 (en) 2014-07-10
DK2488157T3 (da) 2021-01-25
EP2488157A1 (en) 2012-08-22
SI2488157T1 (sl) 2021-02-26
US20120263766A1 (en) 2012-10-18
BR112012008969A2 (pt) 2020-06-23
PT2488157T (pt) 2021-02-05
ZA201202595B (en) 2023-07-26
PL2488157T3 (pl) 2021-06-28

Similar Documents

Publication Publication Date Title
CL2012000948A1 (es) Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.
EA201590179A1 (ru) Комбинированная терапия copd
PE20140101A1 (es) Formulacion para inhalacion que comprende aclidinio
UY31235A1 (es) Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
JP2007106777A5 (https=)
WO2011076841A3 (en) Combination therapy for copd
JP2010132695A5 (https=)
BRPI0905775A2 (pt) composição farmacêutica para inalação, método de tratar uma condição respiratória, uso de aclidínio, aclidínio, formulação e dispositivo inalador
WO2010138884A3 (en) Respiratory delivery of active agents
CL2014002808A1 (es) Dispositivo de inhalacion plegable para usar con un dispensador de inhalador de dosis medida, dicho dispositivo comprende un miembro de la extremidad de salida incluyendo una boquilla, un miembro de la extremidad de entrada incluyendo un orificio de entrada, y un miembro de manguito tubular; metodo para administrar una dosis de un medicamento; metodo para formar un dispositivo de inhalacion plegable.
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
JP2014530231A5 (https=)
PE20070951A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
UY34838A (es) Nueva forma de dosificación y formulación
TN2016000262A1 (en) Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
MX2014004364A (es) Composiciones que comprenden sulfato de salbutamol.
MX2022009231A (es) Inhalador de polvo seco y metodo de uso.
DK2089008T3 (da) Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator
PL2146704T3 (pl) Zastosowanie kompozycji zawierającej formoterol i dipropionian beklometazonu do leczenia zaostrzenia astmy
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
AR067459A1 (es) Inhalador
CO2022007719A2 (es) Lata de acero inoxidable para inhaladores dosificadores presurizados
TR200909788A2 (tr) Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
AR089101A1 (es) Formulacion nasal